Trillionaire Elon Musk infrastructure & tunnel group The Boring Company raised $3 billion in Series D funding at $23 billion valuation, founded in 2016 as subsidiary of SpaceX & setup as independent entity in 2018, investors include UAE Entities, Sequoia Capital, Andreessen Horowitz, Temasek, Valor Equity Partners, Vy Capital, Human Capital, Shamal Holding, & Baron Capital. Sep 10, 2026 10th September 2026 | Hong Kong Trillionaire Elon Musk infrastructure & tunnel group The Boring Company has raised $3 billion in Series D funding at $23 billion valuation. The Boring Company was founded in 2016 as a subsidiary of SpaceX & setup as independent entity in 2018. The Boring Company investors include UAE Entities, Sequoia Capital, Andreessen Horowitz, Temasek, Valor Equity Partners, Vy Capital, Human Capital, Shamal Holding, & Baron Capital. "Trillionaire Elon Musk infrastructure & tunnel group The Boring Company raised $3 billion in Series D funding at $23 billion valuation, founded in 2016 as subsidiary of SpaceX & setup as independent entity in 2018, investors include UAE Entities, Sequoia Capital, Andreessen Horowitz, Temasek, Valor Equity Partners, Vy Capital, Human Capital, Shamal Holding, & Baron Capital"

Elon Musk’s The Boring Company has raised an exciting $3 billion in new fundraising, meaning the company, and its underground technology including ‘The Monster’ tra...

Building the AI network for medicine. Announcing its $150M Series C at a $3B valuation to bring Forus to every doctor's office in America. Today, Forus Inc. is announcing that Forus has raised $150 million in Series C financing at a $3 billion valuation, led by Bain Capital Ventures, with every existing institutional investor reinvesting, including Thrive Capital, General Catalyst, Accel, Redpoint, BoxGroup, Pear VC, Avra, Human Capital, Neo, Vast Ventures, and SV Angel. Forus Inc. has now raised more than $300 million in total funding to build the AI network for medicine. Medicine can do things today that sounded impossible a generation ago. New therapies are reaching people with depression after decades without meaningful progress. Gene therapies are changing the course of disease for children born with conditions that were once untreatable. Cancers that were once fatal are becoming conditions people live with for years. More capital is going into discovering new medicines than at any point in history, and AI is accelerating the discovery of new molecules even further. Discovery is only the beginning. Bringing a new drug from discovery to approval still takes more than a decade and billions of dollars. Once approved, it still has to reach the right physicians, get prescribed to the right patients, make it through insurance and distribution, and ultimately get into the patient's hands. A proven medicine can take years to reach most of the people it could help. Forus is building the AI network to make that entire process move faster. Forus Inc. connect the companies developing medicines with the doctors who prescribe them and the patients who need them, along with the payers and pharmacies required to move treatment through the system. Forus Inc. use AI to help medicine move from development through launch and ultimately reach the people it was created for. Building the network. Forus Inc. build that network by giving doctors and patients a platform that gets people onto the treatments their doctors prescribe. Today, doctors and patients often spend weeks or months working through insurance, financial assistance, and fulfillment before treatment starts, and more than a third of patients prescribed high-cost or complex medicines never receive their first dose. Forus closes that gap by giving every prescription its own AI agent, across every drug, payer, and pharmacy in the country, free for doctors and patients. Every person has a different medical history, insurance coverage, and financial situation, which govern how Forus Inc. navigate the supply chain for them. Its agents work like case managers, reasoning through each person's situation, determining what needs to happen next, and taking action across the portals, documents, phone calls, and faxes that the system still runs on. They draw on clinical models, specialized sub-agents, and what Forus Inc. has learned from millions of cases to get each patient from prescription to treatment. Building agents for this problem pushes well beyond automating a standard workflow with an LLM. There is no standard case. Every practice has different systems and processes, every drug and payer has different requirements, and every patient introduces a new combination of clinical history, coverage, eligibility, and cost. An agent has to assemble incomplete and sometimes conflicting information, reason through what is true, decide what to do next, and then act correctly across systems it does not control. Because the agent is responsible for moving a real patient through the process rather than simply producing an answer to a question, its bar for accuracy is near absolute. And Forus gets better as more of the country uses it. Every prescription gives its agents and teams another real case to learn from and expands what Forus Inc. understand about the combinations they will encounter next. Today, Forus supports millions of people across all 50 states, already reaching patients in 85% of U.S. residential ZIP codes. Accelerating new medicines. The same network can help biopharma develop and launch new medicines faster and more efficiently. Bringing a medicine to market requires recruiting the right patients for clinical trials, reaching the physicians whose patients can benefit, securing coverage and distribution, and understanding where adoption or access is breaking. Forus combines real-time visibility into how medicine is moving with connectivity across the doctors, patients, pharmacies, and payers involved, creating one network that can support these critical steps of development and launch. Nine of the top 15 global biopharma companies already work with Forus, alongside many fast-growing biotechs. If developing and launching each new medicine becomes faster, more efficient, and more predictable, biopharma can invest in more drugs for more diseases. That is the larger opportunity: not just helping individual medicines reach more people, but increasing how much new medicine can be pursued in the first place. More of the science being discovered can become treatment for real patients. Its goal is to put Forus in every doctor's office in the country, so every disease can be treated with the best medicine science can offer. The more medicine that moves through Forus, the more capable the network becomes at helping develop new treatments, launch them, and get them to the patients who need them. Medicine is advancing faster than at any point in history. Forus Inc. is building Forus to make sure everything required to turn that science into treatment can keep up. Forus Inc. will keep building until science is the only limit to medicine.